CS411091A3 - Phenylcarbamates, process of their preparation and pharmaceuticalcomposition comprising thereof - Google Patents

Phenylcarbamates, process of their preparation and pharmaceuticalcomposition comprising thereof Download PDF

Info

Publication number
CS411091A3
CS411091A3 CS914110A CS411091A CS411091A3 CS 411091 A3 CS411091 A3 CS 411091A3 CS 914110 A CS914110 A CS 914110A CS 411091 A CS411091 A CS 411091A CS 411091 A3 CS411091 A3 CS 411091A3
Authority
CS
Czechoslovakia
Prior art keywords
compound
ethyl
formula
free base
pharmaceutically acceptable
Prior art date
Application number
CS914110A
Other languages
Czech (cs)
English (en)
Inventor
Albert Enz
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS411091(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of CS411091A3 publication Critical patent/CS411091A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CS914110A 1987-03-04 1991-12-27 Phenylcarbamates, process of their preparation and pharmaceuticalcomposition comprising thereof CS411091A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
CS411091A3 true CS411091A3 (en) 1992-12-16

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
CS914110A CS411091A3 (en) 1987-03-04 1991-12-27 Phenylcarbamates, process of their preparation and pharmaceuticalcomposition comprising thereof

Country Status (29)

Country Link
US (1) US5602176A (da)
JP (3) JP2625478B2 (da)
KR (1) KR0133686B1 (da)
AT (1) AT394190B (da)
AU (1) AU618949B2 (da)
BE (1) BE1001467A3 (da)
CA (1) CA1307003C (da)
CH (1) CH675720A5 (da)
CS (1) CS411091A3 (da)
CY (1) CY1735A (da)
DK (1) DK175762B1 (da)
ES (1) ES2010527A6 (da)
FI (1) FI89165C (da)
FR (1) FR2611707B1 (da)
GB (1) GB2203040C (da)
GR (1) GR1000023B (da)
HK (1) HK110093A (da)
HU (1) HU201906B (da)
IE (1) IE61714B1 (da)
IL (1) IL85609A (da)
IT (1) IT1219853B (da)
LU (2) LU87150A1 (da)
MY (1) MY103225A (da)
NL (1) NL195004C (da)
NZ (1) NZ223714A (da)
PT (1) PT86875B (da)
SA (1) SA93140384B1 (da)
SE (1) SE8800731L (da)
ZA (1) ZA881584B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014973A2 (es) 2005-08-04 2007-02-08 Interquim, S.A. Procedimiento para la obtención de carbamatos de fenilo

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5712282A (en) * 1994-04-15 1998-01-27 Masaomi Iyo Method for therapeutically treating tardive dyskinesia and uses thereof
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
EP0951284B1 (en) * 1996-12-18 2003-10-08 Teva Pharmaceutical Industries, Ltd. Phenylethylamine derivatives
HU229507B1 (en) 1996-12-18 2014-01-28 Technion Res & Dev Foundation 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
NZ510683A (en) 1998-10-01 2003-09-26 Novartis Ag Sustained release oral formulations of rivastigmine
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
WO2000033840A1 (en) * 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ATE543545T1 (de) 2005-09-15 2012-02-15 Sony Computer Entertainment Inc Beschaffung einer eingabe zum kontrollieren der ausführung eines spielprogrammes
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CA2634166C (en) * 2005-12-09 2016-03-29 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP2125709A2 (en) * 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (en) * 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
WO2011076621A2 (de) 2009-12-22 2011-06-30 Acino Ag Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6088422B2 (ja) 2010-03-29 2017-03-01 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
MX346185B (es) 2010-11-15 2017-03-10 Agenebio Inc Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
SI2468274T1 (sl) 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
EP2752188B1 (en) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
DK3033082T3 (da) 2013-08-16 2021-09-20 Univ Maastricht Behandling af kognitiv svækkelse med pde4-hæmmer
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014973A2 (es) 2005-08-04 2007-02-08 Interquim, S.A. Procedimiento para la obtención de carbamatos de fenilo

Also Published As

Publication number Publication date
DK112588A (da) 1988-09-05
FI89165C (fi) 1993-08-25
FR2611707B1 (fr) 1990-04-20
JPH09165362A (ja) 1997-06-24
SE8800731A0 (sv) 1988-09-05
NL195004B (nl) 2003-07-01
KR0133686B1 (ko) 1998-04-21
GB2203040B (en) 1990-10-24
AU1255488A (en) 1988-09-08
CH675720A5 (da) 1990-10-31
JPH09118617A (ja) 1997-05-06
NL8800436A (nl) 1988-10-03
SE8800731L (sv) 1988-09-05
ATA55188A (de) 1991-08-15
IE880583L (en) 1988-09-04
BE1001467A3 (fr) 1989-11-07
SA93140384B1 (ar) 2006-04-04
HUT49325A (en) 1989-09-28
GR880100125A (en) 1989-01-31
SE8800731D0 (sv) 1988-03-02
NZ223714A (en) 1994-05-26
LU87150A1 (fr) 1988-11-17
CY1735A (en) 1994-06-03
IL85609A0 (en) 1988-08-31
FI880972A0 (fi) 1988-03-02
AU618949B2 (en) 1992-01-16
IT8847693A0 (it) 1988-03-04
PT86875A (pt) 1988-04-01
PT86875B (pt) 1992-05-29
GB2203040A (en) 1988-10-12
US5602176A (en) 1997-02-11
IE61714B1 (en) 1994-11-30
DK175762B1 (da) 2005-02-14
HU201906B (en) 1991-01-28
DK112588D0 (da) 1988-03-02
CA1307003C (en) 1992-09-01
MY103225A (en) 1993-05-29
GR1000023B (el) 1990-01-31
IT1219853B (it) 1990-05-24
FI89165B (fi) 1993-05-14
KR880011088A (ko) 1988-10-26
IL85609A (en) 1992-07-15
ES2010527A6 (es) 1989-11-16
JP2859225B2 (ja) 1999-02-17
NL195004C (nl) 2003-11-04
FI880972A (fi) 1988-09-05
GB8804888D0 (en) 1988-03-30
GB2203040C (en) 2014-07-30
HK110093A (en) 1993-10-29
AT394190B (de) 1992-02-10
ZA881584B (en) 1989-11-29
JP2625478B2 (ja) 1997-07-02
JPS63238054A (ja) 1988-10-04
LU90297I2 (fr) 1998-12-07
FR2611707A1 (fr) 1988-09-09

Similar Documents

Publication Publication Date Title
CS411091A3 (en) Phenylcarbamates, process of their preparation and pharmaceuticalcomposition comprising thereof
Manoury et al. Synthesis of a series of compounds related to betaxolol, a new. beta. 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases
Goldberg et al. Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture
DE69610290T2 (de) Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin
DE3805744C2 (de) Phenylcarbamate zur Hemmung der Acetylcholinesterase
EP1727539B1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
KR20160058760A (ko) 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법
US6518314B1 (en) Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6310252B1 (en) [(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives and their use as local anaesthetics
Woods et al. Exogenous tyrosine potentiates the methylphenidate-induced increase in extracellular dopamine in the nucleus accumbens: a microdialysis study
CZ240994A3 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine and its use for treating neurodegenerative disorders
DE3844992B4 (de) Hydrogentartrat eines Phenylcarbamats
NL195081C (nl) Fenylcarbamaat.
EA006897B1 (ru) Фармацевтическая композиция для лечения заболеваний, характеризующихся снижением и/или нарушением когнитивных функций
Cannon et al. Resorcinol congeners of dopamine derived from benzocycloheptene and indan
Jackman et al. Synthesis, β-adrenoceptor pharmacology and toxicology of S-(−)-1-(4-(2-ethoxyethoxy) phenoxy)-2-hydroxy-3-(2-(3, 4-dimethoxyphenyl) ethylamino) propane hydrochloride, a short acting β1-specific antagonist
Weinstock et al. Differential effects of d-and l-propranolol on dopamine turnover stimulated by oxotremorine in striatal and mesolimbic areas of rat brain
EP1282414B1 (en) Felbamate derived compounds for treating neuropathic pain
Nahorski et al. Increased cerebral cyclic GMP concentration induced by muscarinic cholinergic agonists and prostaglandin F2alpha [proceedings].
CZ20023718A3 (cs) Opticky aktivní 2-aminotetralinové deriváty, způsob jejich výroby a farmaceutický prostředek
RU2193555C2 (ru) Метил-изопропил[(3-н-пропоксифенокси)этил]амин или его фармацевтически приемлемая соль, способы его получения (варианты), фармацевтическая композиция, способ местной анестезии

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic